Rinvoq For Rheumatoid Arthritis
Since December 2019, Upadacitinib has been approved in few countries such as Germany. Upadacitinib (Rinvoq is the trade name) has proved its efficacy in treating the severe active form of rheumatoid arthritis.
Then, its use has become recommended in other countries such as U.S.A and England.
The National Institute of Health (NIH) has lately recommended Rinvoq for moderate to severe RA patients who showed no response to methotrexate and other treatment lines.